New capital brings primary-cell functional data to more discovery teams, on demand

新资本助力按需向更多发现团队提供原代细胞功能数据

MONTREAL

蒙特利尔

,

，

Oct. 26, 2026

2026年10月26日

/PRNewswire/ -- DropGenie, a functional biology company generating decision-ready discovery data from patient-derived cells, has secured $5 million in Seed+ financing. BDC Thrive Venture Fund invested alongside Skeleton Key, with participation from Merck Global Health Innovation Fund, CQDM, Real Ventures and Anges Quebec..

/美通社/ -- DropGenie 是一家功能生物学公司，致力于从患者衍生细胞中生成可用于决策的发现数据，该公司已顺利完成 500 万美元的 Seed+ 轮融资。BDC Thrive 风险投资基金与 Skeleton Key 共同领投，默克全球健康创新基金、CQDM、Real Ventures 和 Anges Quebec 也参与了本轮投资。

The financing accelerates commercialization of DropGenie's first product, which miniaturizes gene editing workflows to enable high-efficiency edits directly in primary patient cells, using up to 100 times fewer cells and far less reagent than conventional workflows. The product is already being integrated into workflows at major global pharma, biotech, and research organizations.

这笔融资加速了DropGenie首款产品的商业化进程。该产品将基因编辑工作流程微型化，能够直接在原代患者细胞中实现高效编辑，与传统流程相比，细胞用量减少多达100倍，试剂用量也大幅降低。目前，全球主要的制药、生物技术和研究机构已在他们的工作流程中整合该产品。

Building on that foundation, DropGenie is expanding how customers can work with the company: running protocols in their own labs, partnering to run studies as a service, or forming strategic data partnerships that build standardized functional datasets from primary patient cells..

在此基础上，DropGenie 正在拓展客户与公司的合作模式：包括在客户自有实验室中运行实验方案、以研究即服务（Study-as-a-Service）的方式开展合作研究，或建立战略数据合作伙伴关系，从原代患者细胞构建标准化的功能数据集。

'Primary human cells hold the answers drug developers need, but they've been too scarce to study at scale,' said Alison Hirukawa, Co-founder and CEO of DropGenie. 'We make those experiments practical, and BDC Thrive Fund helps us bring that to more teams, faster.'

“原代人类细胞蕴含着药物研发人员所需的答案，但因其过于稀缺，难以开展大规模研究。”DropGenie联合创始人兼首席执行官艾莉森·平川表示，“我们使这些实验变得切实可行，而BDC Thrive基金帮助我们更快地将这一能力推广至更多团队。”

BDC's $350 million Thrive Venture Fund invests in women-led Canadian technology companies from pre-seed through Series B. Its investment in DropGenie's Seed+ financing adds a long-term Canadian partner at the board level as the company scales.

BDC的3.5亿加元Thrive风险投资基金投资于从预种子轮到B轮的由女性领导的加拿大科技公司。其对DropGenie Seed+融资的投资，为该公司在扩张阶段增加了一位长期的加拿大董事会层面合作伙伴。

'DropGenie is building critical infrastructure for the future of drug discovery by making high-quality, human-relevant biological data more accessible and scalable,' said Mona Minhas, Managing Partner, BDC Thrive Venture Fund. 'We see an opportunity to build a globally important company from Canada, and Alison has the scientific depth, ambition and vision to lead it.

“DropGenie 正在通过提高高质量、与人类相关的生物数据的可访问性和可扩展性，为药物发现的未来构建关键基础设施，”BDC Thrive 风险投资基金的管理合伙人 Mona Minhas 表示。“我们看到了从加拿大打造一家具有全球重要性的公司的机遇，而 Alison 具备引领这一使命所需的科学深度、雄心与愿景。”

We're proud to back her and the DropGenie team as they scale globally.'.

我们自豪地支持她以及DropGenie团队在全球范围内的扩张。

'We look for science companies that are accelerating discovery with innovative technology and DropGenie is doing just that by generating reliable experimentation data to enable the adaptation of AI-assisted innovation in the future,' said Ann Lai, Managing Partner of Skeleton Key. 'We're excited to have BDC Thrive Fund join the Board and show support for a homegrown deep-tech company.'.

Skeleton Key 的管理合伙人 Ann Lai 表示：“我们寻找那些通过创新技术加速科学发现的公司，而 DropGenie 正是通过生成可靠的实验数据，为未来适应人工智能辅助的创新铺平道路，完美契合这一标准。我们很高兴看到 BDC Thrive Fund 加入董事会，并对这家本土成长的深科技公司提供支持。”

DropGenie is working with leading partners across primary-cell applications ahead of its broader rollout early next year. Teams looking to generate functional data through the platform, services, or data partnerships can learn more at

DropGenie 正与初级细胞应用领域的领先合作伙伴携手合作，为明年年初的更广泛推广做准备。希望通过该平台、服务或数据合作伙伴关系生成功能性数据的团队，可在以下网址了解更多详情：

www.dropgenie.com

www.dropgenie.com

.

。

About DropGenie

关于 DropGenie

DropGenie is a functional biology company making large-scale experiments in primary patient cells practical. Its automated microfluidic platform uses up to 100 times fewer cells than conventional methods, and the company offers that capability as a service and through strategic data partnerships. Based in Montreal and Boston, DropGenie supports cell therapy, functional genomics, and AI-driven drug development.

DropGenie 是一家功能生物学公司，致力于使在原代患者细胞中进行大规模实验变得切实可行。其自动化微流控平台所需的细胞数量比传统方法减少多达 100 倍，该公司通过服务提供以及战略数据合作伙伴关系来提供这一能力。DropGenie 总部位于蒙特利尔和波士顿，支持细胞治疗、功能基因组学以及人工智能驱动的药物研发。

Learn more at .

了解更多，请访问。

www.dropgenie.com

www.dropgenie.com

.

。

SOURCE DropGenie

来源：DropGenie

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示